Abstract:The clinical success of anticancer therapy is usually limited by drug resistance and the metastatic dissemination of cancer cells. Mitochondria are essential generators of cellular energy and play a crucial role in sustaining cell survival and metastatic escape. Selective drug strategies targeting mitochondria are able to rewire mitochon-drial metabolism and may provide an alternative paradigm to treat many aggressive cancers with high efficiency and low toxicity. Here, we present a pseudo-stealthy mitochondria-targeted pro-nanotaxane and test it against recurrent and metastatic tumor xenografts. The nanoparticle encapsulates a mitochondria-targetable pro-taxane agent, which can be converted into the chemically unmodified cabazitaxel drug, with further surface cloaking with a low-density lipophilic triphenylphosphonium cation. The resultant nanotaxane could be effectively taken up by cells and consequently specifically localized to the mitochondria. The in situ activated cabazitaxel causes mitochondrial dysfunction and ultimately results in potent cell apoptosis. After intravenous administration to animals, pro-nanotaxane mimics the stealthy behavior of polyethylene glycol-cloaked nanoparticles to provide a long circulation time. The antitumor efficacy of this mitochondria-targeted system was validated in multiple preclinical drug-resistant tumor models. Notably, in a patient-derived metastatic melanoma model that was initially pretreated with cabazitaxel, nanotaxane administration not only produced durable tumor reduction but also substantially suppressed metastatic recurrence. Taken together, these results demonstrate that this combination of a pseudo-stealthy platform with a rationally designed pro-drug is an attractive approach to target mitochondria and enhance drug efficacy.

Emerging nanotaxanes for cancer therapy

Polydopamine-Functionalized CA-(PCL-ran-PLA) Nanoparticles for Target Delivery of Docetaxel and Chemo-photothermal Therapy of Breast Cancer.

Emerging Nanomedicines of Paclitaxel for Cancer Treatment

Taxanes prodrug-based nanomedicines for cancer therapy

How Nanotechnology Can Enhance Docetaxel Therapy

Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.

Recent progress in nanoformulations of cabazitaxel

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Taxane anticancer agents: a patent perspective

Current development in nanoformulations of docetaxel.

Current Development in Nanoformulations of Docetaxel

Recent Strategies of Carbon Dots Based Nanodrugs for Enhanced Emerging Antitumor Modalities

Exploration and Outlook of Recent Applications of Paclitaxel in Breast Cancer Treatment

Advances in nano-drug delivery systems for docetaxel

A multiscale approach to targeted docetaxel formulations: combination therapy, nanotechnology, electrospinning and 3D printing—a review

Nanomaterials for cancer therapy: current progress and perspectives

Drug nanocrystals for cancer therapy.

Nanomaterials in Cancer-Therapy Drug Delivery System

Enhanced in Vivo Antitumor Efficacy of Dual-Functional Peptide-Modified Docetaxel Nanoparticles Through Tumor Targeting and Hsp90 Inhibition.

Paclitaxel nanosuspensions for targeted chemotherapy - nanosuspension preparation, characterization, and use.

Study on the Effect and Mechanism of Paclitaxel-Succini Acid Drug-Loaded Nanofibers in Treating Lung Cancer.